Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related LHCG
UPDATE: Credit Suisse Upgrades LHC Group to Outperform, Sees 2015 As An Inflection
Benzinga's Top Upgrades
Related GEVA
Can The Rally In Synageva Biopharma Shares Continue?
Synageva BioPharma Completes Rolling Submission Of Biologics License Application To The FDA For Sebelipase Alfa

Analysts at Deutsche Bank downgraded LHC Group (NASDAQ: LHCG) from “buy” to “hold.” The target price for LHC Group is set to $23. LHC Group's shares closed at $23.36 yesterday.

Analysts at JP Morgan downgraded Synageva BioPharma (NASDAQ: GEVA) from “overweight” to “neutral.” The target price for Synageva BioPharma has been lowered from $57 to $50. Synageva BioPharma's shares closed at $45.79 yesterday.

Analysts at Canaccord Genuity downgraded Rent-A-Center (NASDAQ: RCII) from “buy” to “hold.” The target price for Rent-A-Center has been lowered from $42.00 to $37.00. Rent-A-Center's shares closed at $35.80 yesterday.

McNicoll Lewis Vlak downgraded Transcept Pharmaceuticals (NASDAQ: TSPT) from “buy” to “hold.” The target price for Transcept Pharmaceuticals is set to $3. Transcept Pharmaceuticals' shares closed at $3.09 yesterday.

Latest Ratings for LHCG

DateFirmActionFromTo
Dec 2014Credit SuisseUpgradesUnderperformOutperform
Nov 2014BairdUpgradesUnderperformNeutral
Aug 2014Credit SuisseMaintainsUnderperform

View More Analyst Ratings for LHCG
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (LHCG + GEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters